Monitoring the amyloid beta-peptide in vivo – caveat emptor

Blennow, 2006, Alzheimer's disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7 Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol., 82, 239, 10.1007/BF00308809 Dodart, 2005, Overview on rodent models of Alzheimer's disease, Curr. Protoc. Neurosci., 10.1002/0471142301.ns0922s33 Hardy, 1991, Amyloid deposition as the central event in the aetiology of Alzheimer's disease, Trends Pharmacol. Sci., 12, 383, 10.1016/0165-6147(91)90609-V Deshpande, 2006, Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons, J. Neurosci., 26, 6011, 10.1523/JNEUROSCI.1189-06.2006 Levy, 1990, Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage Dutch type, Science, 248, 1124, 10.1126/science.2111584 Citron, 1992, Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production, Nature, 360, 672, 10.1038/360672a0 Suzuki, 1994, An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants, Science, 264, 1336, 10.1126/science.8191290 Motte, 1989, Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain, Acta Neuropathol., 77, 535, 10.1007/BF00687256 Prasher, 1998, Molecular mapping of Alzheimer-type dementia in Down's syndrome, Ann. Neurol., 43, 380, 10.1002/ana.410430316 Gotz, 2001, Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils, Science, 293, 1491, 10.1126/science.1062097 Oddo, 2003, Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease, Neurobiol. Aging, 24, 1063, 10.1016/j.neurobiolaging.2003.08.012 Walsh, 2007, A beta oligomers – a decade of discovery, J. Neurochem., 101, 1172, 10.1111/j.1471-4159.2006.04426.x Salloway, 2008, Disease-modifying therapies in Alzheimer's disease, Alzheimers. Dement., 4, 65, 10.1016/j.jalz.2007.10.001 Finder, 2007, Amyloid-beta aggregation, Neurodegener. Dis., 4, 13, 10.1159/000100355 Deane, 2007, Role of the blood–brain barrier in the pathogenesis of Alzheimer's disease, Curr. Alzheimer Res., 4, 191, 10.2174/156720507780362245 Portelius, 2008, Targeted proteomics in Alzheimer's disease: focus on amyloid-beta, Expert. Rev. Proteom., 5, 225, 10.1586/14789450.5.2.225 Bibl, 2007, Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias, Mol. Psychiatry, 12, 671, 10.1038/sj.mp.4001967 Simonsen, 2007, Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods, Dement. Geriatr. Cogn Disord., 23, 246, 10.1159/000100020 Vanderstichele, 2005, Amino-truncated beta-amyloid 42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment, Clin. Chem., 51, 1650, 10.1373/clinchem.2005.051201 Vanderstichele, 2000, Standardization of measurement of beta-amyloid (1–42) in cerebrospinal fluid and plasma, Amyloid, 7, 245, 10.3109/13506120009146438 Mueller, 2005, Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI), Alzheimers Dement., 1, 55, 10.1016/j.jalz.2005.06.003 Shaw, 2008, PENN biomarker core of the Alzheimer's disease neuroimaging initiative, Neurosignals, 16, 19, 10.1159/000109755 Schoonenboom, 2005, Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid, Clin. Chem., 51, 1057, 10.1373/clinchem.2005.048629 LeVine, 2004, Alzheimer's beta-peptide oligomer formation at physiologic concentrations, Anal. Biochem., 335, 81, 10.1016/j.ab.2004.08.014 Kayed, 2003, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science, 300, 486, 10.1126/science.1079469 Georganopoulou, 2005, Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proc. Natl. Acad. Sci. U.S.A., 102, 2273, 10.1073/pnas.0409336102 Santos, 2007, Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer, J. Alzheimers Dis., 11, 117, 10.3233/JAD-2007-11114 Barghorn, 2005, Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer's disease, J. Neurochem., 95, 834, 10.1111/j.1471-4159.2005.03407.x Bohrmann, 1999, Endogenous proteins controlling amyloid beta-peptide polymerisation. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues, J. Biol. Chem., 274, 15990, 10.1074/jbc.274.23.15990 Rozga, 2007, The binding constant for amyloid Abeta40 peptide interaction with human serum albumin, Biochem. Biophys. Res. Commun., 364, 714, 10.1016/j.bbrc.2007.10.080 Hammad, 1997, Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide, J. Biol. Chem., 272, 18644, 10.1074/jbc.272.30.18644 Tokuda, 2000, Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides, Biochem. J., 348, 359, 10.1042/0264-6021:3480359 Deane, 2004, LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms, Neuron, 43, 333, 10.1016/j.neuron.2004.07.017 Bell, 2007, Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system, J. Cereb. Blood Flow Metab., 27, 909, 10.1038/sj.jcbfm.9600419 Sagare, 2007, Clearance of amyloid-beta by circulating lipoprotein receptors, Nat. Med., 13, 1029, 10.1038/nm1635 Kuo, 2000, Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma, Biochem. Biophys. Res. Commun., 268, 750, 10.1006/bbrc.2000.2222 Kuo, 1999, High levels of circulating Abeta 42 are sequestered by plasma proteins in Alzheimer's disease, Biochem. Biophys. Res. Commun., 257, 787, 10.1006/bbrc.1999.0552 Slemmon, 2007, Distribution of Abeta peptide in whole blood, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 846, 24, 10.1016/j.jchromb.2006.08.003 Lanz, 2008, Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies, J. Neurosci. Methods, 169, 16, 10.1016/j.jneumeth.2007.11.009 Bateman, 2006, Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo, Nat. Med., 12, 856, 10.1038/nm1438 Brodbelt, 2007, CSF pathways: a review, Br. J. Neurosurg., 21, 510, 10.1080/02688690701447420 Silverberg, 2003, Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis, Lancet Neurol., 2, 506, 10.1016/S1474-4422(03)00487-3 Wilson, 2006, Normal pressure hydrocephalus, Clin. Geriatr. Med., 22, 935, 10.1016/j.cger.2006.06.010 Kapaki, 2007, Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease, Eur. J. Neurol., 14, 168, 10.1111/j.1468-1331.2006.01593.x Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta 42 in humans, Ann. Neurol., 59, 512, 10.1002/ana.20730 Savolainen, 1999, Prevalence of Alzheimer's disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study, Acta Neurochir. (Wien.), 141, 849, 10.1007/s007010050386 de Leon, 2007, Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease, Ann. N. Y. Acad. Sci., 1097, 114, 10.1196/annals.1379.012 Abdullah, 2007, The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels, Neurosci. Lett., 428, 53, 10.1016/j.neulet.2007.09.058 Li, 1998, Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets, Lab. Invest., 78, 461 Skovronsky, 2001, Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C, J. Biol. Chem., 276, 17036, 10.1074/jbc.M006285200 Tang, 2006, Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease, J. Neurol. Sci., 240, 53, 10.1016/j.jns.2005.09.002 Olsson, 2003, Unaltered plasma levels of beta-amyloid (1–40) and beta-amyloid (1–42) upon stimulation of human platelets, Dement. Geriatr. Cogn. Disord., 16, 93, 10.1159/000070681 Kuo, 2000, Elevated Abeta 42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of Abeta PP metabolism, Am. J. Pathol., 156, 797, 10.1016/S0002-9440(10)64947-4 Askanas, 2006, Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition, Neurology, 66, S39, 10.1212/01.wnl.0000192128.13875.1e Siemers, 2007, Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase, Clin. Neuropharmacol., 30, 317, 10.1097/WNF.0b013e31805b7660 Smirnov, 2008, Differential processing and secretion of Abeta peptides and sAPPalpha in human platelets is regulated by thrombin and prostaglandine 2, Neurobiol. Aging Lockhart, 2006, Imaging Alzheimer's disease pathology: one target, many ligands, Drug Discov. Today, 11, 1093, 10.1016/j.drudis.2006.10.008 Nordberg, 2008, Amyloid imaging in Alzheimer's disease, Neuropsychologia, 46, 1636, 10.1016/j.neuropsychologia.2008.03.020 Lockhart, 2007, PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis, Brain, 130, 2607, 10.1093/brain/awm191 Pike, 2007, Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease, Brain, 130, 2837, 10.1093/brain/awm238 Rowe, 2007, Imaging beta-amyloid burden in aging and dementia, Neurology, 68, 1718, 10.1212/01.wnl.0000261919.22630.ea Kemppainen, 2007, PET amyloid ligand [11C] PIB uptake is increased in mild cognitive impairment, Neurology, 68, 1603, 10.1212/01.wnl.0000260969.94695.56 Nicoll, 2003, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report, Nat. Med., 9, 448, 10.1038/nm840 Holmes, 2008, Long-term effects of Abeta 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2 Kadir, 2008, Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease, Ann. Neurol, 10.1002/ana.21345 Forsberg, 2007, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol. Aging Rowe, 2008, Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, Lancet Neurol., 7, 129, 10.1016/S1474-4422(08)70001-2 Scahill, R.I. and Fox, N.C. (2007) Longitudinal imaging in dementia. Br. J. Radiol., 80 Spec No. 2 S92–S98 Devanand, 2007, Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease, Neurology, 68, 828, 10.1212/01.wnl.0000256697.20968.d7 Kinkingnehun, 2008, VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study, Neurology, 70, 2201, 10.1212/01.wnl.0000303960.01039.43 Fox, 2005, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology, 64, 1563, 10.1212/01.WNL.0000159743.08996.99 Siemers, 2006, New pathways in drug discovery for Alzheimer's disease, Curr. Neurol. Neurosci. Rep., 6, 372, 10.1007/s11910-996-0017-8 Phelps, 1983, Positron computed tomography for studies of myocardial and cerebral function, Ann. Intern. Med., 98, 339, 10.7326/0003-4819-98-3-339 Silverman, 2001, Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome, JAMA, 286, 2120, 10.1001/jama.286.17.2120 Drzezga, 2008, Concept of functional imaging of memory decline in Alzheimer's disease, Methods, 44, 304, 10.1016/j.ymeth.2007.02.002 Drzezga, 2005, Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET, J. Nucl. Med., 46, 1625 Eustache, F. et al. (2004) ‘In the course of time’: a PET study of the cerebral substrates of autobiographical amnesia in Alzheimer's disease. Brain 127, 1549 Teipel, 2006, Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease, Neurobiol. Aging, 27, 681, 10.1016/j.neurobiolaging.2005.03.015 Stomrud, 2007, Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly, Dement. Geriatr. Cogn. Disord., 24, 118, 10.1159/000105017 Schonknecht, 2007, Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia, Neurosci. Lett., 416, 39, 10.1016/j.neulet.2007.01.070 Gilman, 2005, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, 64, 1553, 10.1212/01.WNL.0000159740.16984.3C Grossman, 2005, Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Ann. Neurol., 57, 721, 10.1002/ana.20477 de Leon, 2007, Longitudinal CSF isoprostane and MRI atrophy in the progression to AD, J. Neurol., 254, 1666, 10.1007/s00415-007-0610-z Galasko, 2007, Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals, Alzheimer Dis. Assoc. Disord., 21, 292, 10.1097/WAD.0b013e31815d1048 Nitsch, 2000, The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease, Ann. Neurol., 48, 913, 10.1002/1531-8249(200012)48:6<913::AID-ANA12>3.0.CO;2-S Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 Milne, 2008, Human biochemistry of the isoprostane pathway, J. Biol. Chem., 283, 15533, 10.1074/jbc.R700047200